Small Cap Active Stocks: FuelCell Energy (NASDAQ:FCEL), Ariad Pharmaceuticals (NASDAQ:ARIA), KB Home (NYSE:KBH), Endocyte (NASDAQ:ECYT)

Shares of Plug Power Inc. (NASDAQ:FCEL) fell 9% on Friday, and the stock was moving toward ending the week down nearly 20% as investors’ enthusiasm for it seemed to have dried up — at least for now. FuelCell Energy Inc (NASDAQ:FCEL) stock performance was 6.64% in last session and finished the day at $2.57. Traded volume was 29.87million shares in the last session and the average volume of the stock remained 20.77million shares. The beta of the stock remained 2.35. FuelCell Energy Inc (NASDAQ:FCEL) insider ownership is 0.80%.

Ariad Pharmaceuticals (NASDAQ:ARIA) Insider Timothy P. Clackson unloaded 6,667 shares of the stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $7.89, for a total transaction of $52,602.63. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) dropped -3.57 percent to $7.84 Friday on volume of 13.35million shares. The intra-day range of the stock was $7.76 to $8.23. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has a market capitalization of $1.46billion.

KB Home (NYSE:KBH) has received an average recommendation of “Hold” from the twenty-seven analysts that are currently covering the company, American Banking News reports. KB Home (NYSE:KBH)’s stock on Mar 21, 2014 reported a decrease of -2.31% to the closing price of $17.79. Its fifty two weeks range is $15.48-$25.14. The total market capitalization recorded $1.68billion. The overall volume in the last trading session was 14.66million shares. In its share capital, KBH has 83.74million outstanding shares.

Endocyte, Inc. (NASDAQ:ECYT) stock skyrocketed over 130% today (Friday) after the Indiana-based biopharma won market approval for its first drug, a cancer therapeutic called “vintafolide.” The drug was developed in collaboration with Merck & Co. On Friday, shares of Endocyte, Inc. (NASDAQ:ECYT) advanced 92.42% to close the day at $28.17. Company return on investment (ROI) is -20.70% and its monthly performance is recorded as 89.44%. Endocyte, Inc. (NASDAQ:ECYT) quarterly revenue growth is 179.74%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone